logo
Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

Toronto, Ontario--(Newsfile Corp. - April 16, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ('Cardiol' or the 'Company'), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announced today that Northwestern University has enrolled the first patient in the pivotal Phase III MAVERIC trial ('MAVERIC') evaluating Cardiol's lead drug candidate CardiolRx™ for the prevention of recurrent pericarditis. This multi-center, randomized, double-blind, placebo-controlled trial is designed to definitively assess the impact of CardiolRx™ on preventing recurrent pericarditis in patients at high risk for disease relapse and to support regulatory approval.
MAVERIC is currently being initiated at pre-eminent cardiovascular clinical research sites throughout the United States under an Investigational New Drug application authorized by the United States Food and Drug Administration ('US FDA'). The MAVERIC Program and Phase III leadership comprises an independent committee of international thought leaders in pericardial disease and clinical trial design: Allan Klein, MD, CM from Cleveland Clinic (MAVERIC Program Chair); Massimo Imazio, MD, FESC from University of Udine, Italy (MAVERIC Program Co-Chair); Paul Cremer, MD from Northwestern University (MAVERIC Trial Principal Investigator); Allen Luis, MBBS, PhD from Mayo Clinic Rochester (MAvERIC-Pilot Principal Investigator); Antonio Abbate, MD, PhD from University of Virginia; and, Stephen Nicholls, MBBS, PhD from Monash University, Melbourne, Australia.
'Recurrent pericarditis remains a challenging condition to manage and can significantly impact patients' quality of life. There is a pressing need for new treatment options earlier in the care pathway, before resorting to second- and third-line therapies such as corticosteroids or IL-1 blockers,' commented Paul C. Cremer, MD, MAVERIC Trial Principal Investigator. 'In collaboration with research centers across the United States, Canada, and Europe, we look forward to completing this important study of a new oral therapy with the potential to improve the treatment paradigm for this underserved patient population.'
'Initiation of the MAVERIC Phase III trial is an important milestone in our Company's efforts to provide a more accessible, non-immunosuppressive therapeutic option for thousands of pericarditis patients. We congratulate Dr. Cremer and his colleagues at Northwestern for recruiting MAVERIC's first patient and we are grateful for the interest shown by our collaborators from other leading pericardial disease centers who will be participating in the study,' said David Elsley, President and CEO of Cardiol Therapeutics. 'Based on the strength and consistency of the data from our Phase II MAvERIC-Pilot study, we believe that CardiolRx™ can make a meaningful difference in the lives of pericarditis patients.'
MAVERIC is a Phase III, multi-center, randomized, double-blind, placebo-controlled trial designed to enroll 110 patients with recurrent pericarditis at approximately 20 clinical sites across the United States, Canada, and Europe. Patients who have been treated with an interleukin-1 ('IL-1") blocker for at least 12 months and are scheduled to have this treatment discontinued, will be randomly assigned to receive either CardiolRx™ or placebo following cessation of the IL-1 blocker. Discontinuation of IL-1 blocker therapy is associated with a high risk for recurrence and has been reported to occur within 12 weeks in up to 75% of patients. The primary clinical objective of the trial will be to assess the impact of CardiolRx™ versus placebo on freedom from a new episode of recurrent pericarditis at 24 weeks. Other clinical endpoints include time to a new episode of pericarditis recurrence, and changes in patient-reported pericarditis chest pain score and changes to the inflammatory marker C-reactive protein.
MAVERIC, formerly referred to as MAVERIC-2, follows positive results from Cardiol's Phase II MAvERIC-Pilot study. Data from MAvERIC-Pilot were previously reported on November 18 at the American Heart Association Scientific Sessions 2024 and showed that patients experienced marked and rapid reductions in both pericarditis pain and inflammation that were maintained throughout the study. In addition, the results demonstrated a substantial reduction in pericarditis episodes per year. Treatment with CardiolRx™ was shown to be safe and well tolerated in a patient population who presented with a high degree of disease burden.
About Pericarditis
Pericarditis refers to inflammation of the pericardium (the membrane or sac that surrounds the heart), which frequently results from a viral infection. Patients may have multiple recurrences following that initial episode, and the primary goal of treatment is recurrence prevention. Symptoms include debilitating chest pain, shortness of breath and fatigue, resulting in physical limitations, reduced quality of life, emergency department visits, and hospitalizations. Significant accumulation of pericardial fluid and scarring can progress to life-threatening constriction of the heart. The only FDA-approved therapy for recurrent pericarditis, launched in 2021, is costly and is primarily used as a third-line intervention. On an annual basis, the number of patients in the United States experiencing at least one recurrence is estimated at 38,000. Approximately 60% of patients with more than one recurrence suffer for more than two years, and one third remain impacted at five years. Hospitalization due to recurrent pericarditis is typically associated with a 6-8-day stay and cost per stay is estimated to range between $20,000 and $30,000 in the United States.
About Cardiol Therapeutics
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small molecule drug candidate, CardiolRx™ (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.
Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration ('US FDA') to conduct clinical studies to evaluate the efficacy and safety of CardiolRx™ in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease of the pericardium which is associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, and results in physical limitations, reduced quality of life, emergency department visits, and hospitalizations, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The ongoing ARCHER trial (NCT05180240) is a Phase II study in acute myocarditis, an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in people less than 35 years of age. The US FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, which includes recurrent pericarditis.
Cardiol is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure - a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding $30 billion annually.
For more information about Cardiol Therapeutics, please visit cardiolrx.com.
Cautionary statement regarding forward-looking information:For further information, please contact:
Trevor Burns, Investor Relations +1-289-910-0855
[email protected]
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/248691

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Caris Life Sciences files for $424M IPO
Caris Life Sciences files for $424M IPO

Yahoo

timean hour ago

  • Yahoo

Caris Life Sciences files for $424M IPO

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Precision medicine company Caris Life Sciences said Monday it expects to raise as much as $423.5 million in an initial public offering. The Irving, Texas-based company plans to list its common stock on the Nasdaq market under the symbol 'CAI,' offering 23.5 million shares at $16 to $18 each. Primarily focused on cancer, Caris' molecular profiling tools use artificial intelligence and machine learning algorithms to analyze disease for early detection, diagnosis, monitoring, therapy selection and drug development. Caris saw year-over-year revenue growth of about 50%, to $120.9 million, in the first quarter of 2025, driven primarily by its molecular profiling services, according to a securities filing. The company received Food and Drug Administration approval for its companion diagnostic test MI Cancer Seek in November. The test identifies cancer patients who may benefit from targeted treatments. Founded in 2008, Caris has identified about 915,000 unique pathogenic mutations to date, of which only about 17,000 were previously known, the company said in its filing. 'We can now identify a person's circulating pathogenic mutations and enable the design of a customized individualized therapy to that specific set of mutations,' David Dean Halbert, Caris founder and CEO, said in the filing. 'We believe this is going to create the opportunity for physicians to use our solutions to effectively prevent various chronic diseases before they ever get started at the earliest of stages.' In April, when the company closed a private funding round worth $168 million, it said it had raised a total of $1.86 billion in capital since 2018. Caris is among a handful of companies exploring a public offering in a medtech IPO market that's showing signs of emerging from a slump. Medical products supplier Medline has said it could go public, and Medtronic plans to separate its diabetes business into a standalone company, potentially through an IPO. Recommended Reading The medtech IPO window is finally open. Or is it? Sign in to access your portfolio

NanoHive Medical Sublicenses DirectSync's Piezoelectric Patents to Explore Development of Hive™ Soft Titanium® 3D Printed Spine Interbody Fusion "Smart Implant"
NanoHive Medical Sublicenses DirectSync's Piezoelectric Patents to Explore Development of Hive™ Soft Titanium® 3D Printed Spine Interbody Fusion "Smart Implant"

Yahoo

time2 hours ago

  • Yahoo

NanoHive Medical Sublicenses DirectSync's Piezoelectric Patents to Explore Development of Hive™ Soft Titanium® 3D Printed Spine Interbody Fusion "Smart Implant"

BOSTON, June 10, 2025 /PRNewswire/ -- NanoHive Medical, LLC, a leading innovative 3D printed spinal implant technology company is pleased to announce that the company has secured the exclusive sublicense of DirectSync Surgical's piezoelectric implantable sensor technology for the field of spinal fusion. DirectSync Surgical had licensed the technology from the University of Kansas. NanoHive is exploring the advancement of successful proof-of-concept research to potentially develop bone stimulating and remote monitoring/data collection sensor technology housed in the company's highly innovative spinal interbody fusion device lattice which is currently commercialized in the company's Hive™ Soft Titanium® portfolio of 3D printed spinal interbody fusion devices. In October 2023, the company reported the initiation of a research collaboration with DirectSync Surgical. Based on the preliminary research generated, the company ascertained that their proprietary rhombic dodecahedron lattice technology was uniquely capable of transferring significant energy from the encapsulated piezoelectric sensor. The company is currently in the process of working with the US Food and Drug Administration (FDA) on the transfer of the Breakthrough Device Designation from DirectSync to NanoHive. Patrick O'Donnell, President & CEO of NanoHive stated, "NanoHive's Soft Titanium® technology is the ideal interbody fusion implant to deliver a sensor with data collection and bone stimulation capability. The company is excited about the prospect of leading the way with the development of a technological leap in the interbody fusion device category. Our view of the future of innovation in spine devices emphasizes that new technologies must demonstrate an improvement to patient virtual care and clinical outcomes as well as connectivity with enabling surgical technologies and artificial intelligence. These advancements must also deliver cost-efficiencies to the various stakeholders involved in the spine patient's episode-of-care. More meaningful and frequent data collection that can ultimately be utilized as a predictive tool will be essential to this vision." About NanoHive Medical LLC NanoHive Medical is a pioneer and leading innovator in 3D printed spinal interbody fusion implants and instrumentation. The company's proprietary, biomimetic Soft Titanium® technology clearly distinguishes their products in the $2.4B U.S. spinal interbody fusion device market. The Hive™ portfolio of interbody fusion devices provide surgeons and their patients ideal biomechanical elastic modulus properties, clear and precise diagnostic imaging capability, osteoblast cell attraction and integration – all features that lead to consistently strong fusion constructs and efficacious clinical experiences. NanoHive Medical is based in Woburn, Massachusetts U.S.A. Contact: Patrick O'Donnell, CEO & President, NanoHive Medical LLC, Website: About DirectSync Surgical DirectSync Surgical is a rising leader in smart patient powered implant devices. With a commitment to innovation and foundational research, the company develops and manufactures advanced tools that empower both spinal and orthopedic professionals to achieve superior surgical outcomes. DirectSync Surgical's products are not available for sale in the US. Contact: Leighton LaPierre, COO, DirectSync Surgical, leighton@ Website: NanoHive Medical, LLC | 12 Gill Street, Suite 4500 | Woburn, MA 01801 | 844-943-5433 View original content to download multimedia: SOURCE NanoHive Medical Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Acadia Healthcare Investor Alert: Scott+Scott Attorneys at Law LLP Investigates Acadia Healthcare Company, Inc.'s Directors and Officers for Breach of Fiduciary Duties
Acadia Healthcare Investor Alert: Scott+Scott Attorneys at Law LLP Investigates Acadia Healthcare Company, Inc.'s Directors and Officers for Breach of Fiduciary Duties

Business Wire

time2 hours ago

  • Business Wire

Acadia Healthcare Investor Alert: Scott+Scott Attorneys at Law LLP Investigates Acadia Healthcare Company, Inc.'s Directors and Officers for Breach of Fiduciary Duties

NEW YORK--(BUSINESS WIRE)-- Scott+Scott Attorneys at Law LLP ('Scott+Scott'), an international securities and consumer rights litigation firm, is investigating whether the leadership of Acadia Healthcare Company, Inc. ('Acadia Healthcare') (NASDAQ: ACHC) breached their fiduciary duties to Acadia Healthcare and its shareholders. Scott+Scott is investigating whether members of the Acadia Healthcare board of directors or senior management failed to manage Acadia Healthcare in an acceptable manner, in breach of their fiduciary duties to Acadia Healthcare, and whether Acadia Healthcare and its shareholders have suffered damages as a result. New York Times published an investigative article detailing unlawful and unethical practices at Acadia Healthcare, including improperly detaining psychiatric patients in Acadia Healthcare facilities against their will. A second article was published on December 7, 2024, detailing fraud and falsification of records at Acadia Healthcare methadone clinics. On April 22, 2025, the New York Times published a third article regarding Acadia Healthcare, alleging suicides and rapes at one of Acadia Healthcare's facilities outside Chicago due in part to insufficient staffing. Acadia Healthcare has acknowledged several governmental investigations on the above, including by the Criminal Division of the U.S. Department of Justice and the Securities and Exchange Commission, as well as Congressional inquiries. In addition, a securities class action lawsuit has been filed against Acadia Healthcare and its top management. What You Can Do – CLICK HERE FOR YOUR OPTIONS AS A SHAREHOLDER If you own shares of Acadia Healthcare, you may have legal claims against Acadia Healthcare's directors and officers. If you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Joe Pettigrew toll-free at (844) 818-6982 or jpettigrew@ About Us Scott+Scott is an international law firm known for its expertise in representing corporate clients, institutional investors, businesses, and individuals harmed by anticompetitive conduct or other forms of wrongdoings, including securities law and shareholder violations. With more than 100 attorneys in nine offices in the United States, as well as three offices in Europe, our advocacy has resulted in significant monetary settlements on behalf of our clients, along with other forms of relief. Our highly experienced attorneys have been recognized for being among the top financial lawyers in 2024 by Lawdragon, WWL: Commercial Litigation 2024, and Legal 500 in Antitrust Civil Litigation, and have received top Chambers 2024 rankings. In addition, we have been recognized by the American Antitrust Institute for the successful litigation of high-stakes anticompetitive claims in the United States. To learn more about Scott+Scott, our attorneys, or complex case resolution, please visit Attorney Advertising

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store